Category Archives: Global News Feed

SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on Tuesday, Nov. 1, 2022 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day prior to the market opening.

More:
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

FOSTER CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that the company will present two abstracts regarding its investigational therapies TERN-501, a THR-? agonist, and TERN-101, an FXR agonist, in clinical development for the treatment of NASH at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, which will be held November 4-8, 2022. The poster abstracts were published in the October 2022 supplement of Hepatology, the peer-reviewed journal of AASLD.

Read more:
Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022

4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T. 4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T.

More here:
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented...

Data support the Company’s lead investigational product candidate sparsentan Data support the Company’s lead investigational product candidate sparsentan

See the article here:
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2022 after the market closes on Thursday, November 3, 2022.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, November 3, 2022, at 4:30 pm ET.

Read this article:
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Read the rest here:
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings